187 related articles for article (PubMed ID: 24124172)
1. Enveloped virus inactivation using neutral arginine solutions and applications in therapeutic protein purification processes.
McCue JT; Selvitelli K; Cecchini D; Brown R
Biotechnol Prog; 2014; 30(1):108-12. PubMed ID: 24124172
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of viruses using novel protein A wash buffers.
Bolton GR; Selvitelli KR; Iliescu I; Cecchini DJ
Biotechnol Prog; 2015; 31(2):406-13. PubMed ID: 25482293
[TBL] [Abstract][Full Text] [Related]
3. Enveloped virus inactivation by caprylate: a robust alternative to solvent-detergent treatment in plasma derived intermediates.
Korneyeva M; Hotta J; Lebing W; Rosenthal RS; Franks L; Petteway SR
Biologicals; 2002 Jun; 30(2):153-62. PubMed ID: 12127317
[TBL] [Abstract][Full Text] [Related]
4. Arginine facilitates inactivation of enveloped viruses.
Yamasaki H; Tsujimoto K; Koyama AH; Ejima D; Arakawa T
J Pharm Sci; 2008 Aug; 97(8):3067-73. PubMed ID: 18186461
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of various processing steps for viral clearance of therapeutic proteins: database analyses of commonly used steps.
Cipriano D; Burnham M; Hughes JV
Methods Mol Biol; 2012; 899():277-92. PubMed ID: 22735960
[TBL] [Abstract][Full Text] [Related]
6. Bracketed generic inactivation of rodent retroviruses by low pH treatment for monoclonal antibodies and recombinant proteins.
Brorson K; Krejci S; Lee K; Hamilton E; Stein K; Xu Y
Biotechnol Bioeng; 2003 May; 82(3):321-9. PubMed ID: 12599259
[TBL] [Abstract][Full Text] [Related]
7. Arginine-enveloped virus inactivation and potential mechanisms.
Meingast C; Heldt CL
Biotechnol Prog; 2020 Mar; 36(2):e2931. PubMed ID: 31622532
[TBL] [Abstract][Full Text] [Related]
8. Virus reduction in an intravenous immunoglobulin by solvent/detergent treatment, ion-exchange chromatography and terminal low pH incubation.
Roberts PL; Dunkerley C; Walker C
Biologicals; 2012 Sep; 40(5):345-52. PubMed ID: 22658506
[TBL] [Abstract][Full Text] [Related]
9. Butyroyl-arginine as a potent virus inactivation agent.
Katsuyama Y; Yamasaki H; Tsujimoto K; Koyama AH; Ejima D; Arakawa T
Int J Pharm; 2008 Sep; 361(1-2):92-8. PubMed ID: 18617337
[TBL] [Abstract][Full Text] [Related]
10. Characterization of operating parameters for XMuLV inactivation by low pH treatment.
Chinniah S; Hinckley P; Connell-Crowley L
Biotechnol Prog; 2016; 32(1):89-97. PubMed ID: 26488618
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of eco-friendly zwitterionic detergents for enveloped virus inactivation.
Conley L; Tao Y; Henry A; Koepf E; Cecchini D; Pieracci J; Ghose S
Biotechnol Bioeng; 2017 Apr; 114(4):813-820. PubMed ID: 27800626
[TBL] [Abstract][Full Text] [Related]
12. Proceedings of the 2019 Viral Clearance Symposium, Session 5: Viral Inactivation.
Ma J
PDA J Pharm Sci Technol; 2022; 76(4):339-348. PubMed ID: 34911831
[TBL] [Abstract][Full Text] [Related]
13. Implementation of a 20-nm pore-size filter in the plasma-derived factor VIII manufacturing process.
Furuya K; Murai K; Yokoyama T; Maeno H; Takeda Y; Murozuka T; Wakisaka A; Tanifuji M; Tomono T
Vox Sang; 2006 Aug; 91(2):119-25. PubMed ID: 16907872
[TBL] [Abstract][Full Text] [Related]
14. Virus inactivation by protein denaturants used in affinity chromatography.
Roberts PL; Lloyd D
Biologicals; 2007 Oct; 35(4):343-7. PubMed ID: 17517521
[TBL] [Abstract][Full Text] [Related]
15. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
16. Virus inactivation by solvent/detergent treatment using Triton X-100 in a high purity factor VIII.
Roberts PL
Biologicals; 2008 Sep; 36(5):330-5. PubMed ID: 18674928
[TBL] [Abstract][Full Text] [Related]
17. Virus elimination during the purification of monoclonal antibodies by column chromatography and additional steps.
Roberts PL
Biotechnol Prog; 2014; 30(6):1341-7. PubMed ID: 25181429
[TBL] [Abstract][Full Text] [Related]
18. Inactivation of virus in intravenous immunoglobulin G using solvent/detergent treatment and pasteurization.
Aghaie A; Pourfatollah AA; Bathaie SZ; Moazzeni SM; Khorsand Mohammad Pour H; Sharifi Z
Hum Antibodies; 2008; 17(3-4):79-84. PubMed ID: 19029665
[TBL] [Abstract][Full Text] [Related]
19. Physiochemical properties of enveloped viruses and arginine dictate inactivation.
Meingast CL; Joshi PU; Turpeinen DG; Xu X; Holstein M; Feroz H; Ranjan S; Ghose S; Li ZJ; Heldt CL
Biotechnol J; 2021 Jul; 16(7):e2000342. PubMed ID: 33877739
[TBL] [Abstract][Full Text] [Related]
20. Virus inactivation in a factor VIII/VWF concentrate treated using a solvent/detergent procedure based on polysorbate 20.
Roberts PL; Lloyd D; Marshall PJ
Biologicals; 2009 Jan; 37(1):26-31. PubMed ID: 18848782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
